References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:https://doi.org/10.3322/caac.21332
- Howlander N, Noone A, Krapcho M, Miller D, Bishop K, Kosary CL ,Yu M ,Ruhl J, Tatalovich Z ,Mariotto A, et al. SEER cancer statistics review, 1975–2014. Bethesda (MD): National Cancer Institute; 2017.
- Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894–906. doi:https://doi.org/10.1016/S0140-6736(15)00046-X
- Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–17. doi:https://doi.org/10.1200/JCO.2008.21.4809
- Smirne C, Grossi G, Pinato DJ, Burlone ME, Mauri FA, Januszewski A, Oldani A, Minisini R, Sharma R, Pirisi M, et al. Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. Dig Liver Dis. 2015;47(6):488–17. doi:https://doi.org/10.1016/j.dld.2015.03.011
- Albayrak S, Zengin K, Tanik S, Bakirtas H, Imamoglu A, Gurdal M. Red cell distribution width as a predictor of prostate cancer progression. Asian Pac J Cancer Prev. 2014;15(18):7781–17. doi:https://doi.org/10.7314/apjcp.2014.15.18.7781
- Podhorecka M, Halicka D, Szymczyk A, Macheta A, Chocholska S, Hus M, Darzynkiewicz Z. Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. Oncotarget. 2016;7(22):32846–17. doi:https://doi.org/10.18632/oncotarget.9055
- Wang FM, Xu G, Zhang Y, Ma LL. Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma. Dis Markers. 2014;2014:860419. doi:https://doi.org/10.1155/2014/860419
- Życzkowski M, Rajwa P, Gabrys E, Jakubowska K, Jantos E, Paradysz A. The relationship between red cell distribution width and cancer-specific survival in patients with renal cell carcinoma treated with partial and radical nephrectomy. Clin Genitourin Cancer. 2018;16(3):e677–e683. doi:https://doi.org/10.1016/j.clgc.2017.12.003
- Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med. 2009;169(5):515–17. doi:https://doi.org/10.1001/archinternmed.2009.11
- Ferrucci L, Guralnik JM, Woodman RC, Bandinelli S, Lauretani F, Corsi AM ,Chaves PHM ,Ershler WB ,Longo DL. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med. 2005;118:1288. e11–1288. e19. doi:https://doi.org/10.1016/j.amjmed.2005.06.039
- Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget. 2016;7(34):54564–17. doi:https://doi.org/10.18632/oncotarget.10515
- Hu L, Li M, Ding Y, Pu L, Liu J, Xie J, Cabanero M, Li J, Xiang R, Xiong S, et al. Prognostic value of RDW in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(9):16027–17. doi:https://doi.org/10.18632/oncotarget.13784
- Zhao T, Cui L, Li A. The significance of RDW in patients with hepatocellular carcinoma after radical resection. Cancer Biomark. 2016;16(4):507–17. doi:https://doi.org/10.3233/CBM-160591
- Howell JA, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J, et al. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget. 2017;8(22):36161–17. doi:https://doi.org/10.18632/oncotarget.15322
- Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986–17. doi:https://doi.org/10.1056/NEJM199912233412607
- Gross AJ, Wolff M, Fandrey J, Miersch WD, Dieckmann KP, Jelkmann W. Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas. Clin Investig. 1994;72(5):337–17. doi:https://doi.org/10.1007/BF00252823
- Lee YS, Vortmeyer AO, Lubensky IA, Vogel TWA, Ikejiri B, Ferlicot S, Benoît G, Giraud S, Oldfield EH, Linehan WM, et al. Coexpression of erythropoietin and erythropoietin receptor in von hippel-lindau disease–associated renal cysts and renal cell carcinoma. Clin Cancer Res. 2005;11(3):1059–17.
- Morais C, Johnson DW, Vesey DA, Gobe GC. Functional significance of erythropoietin in renal cell carcinoma. BMC Cancer. 2013;13:14–17. doi:https://doi.org/10.1186/1471-2407-13-14
- Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4(4):163–17.
- Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med. 2009;133:628–17. doi:https://doi.org/10.1043/1543-2165-133.4.628
- Vayá A, Sarnago A, Fuster O, Alis R, Romagnoli M. Influence of inflammatory and lipidic parameters on red blood cell distribution width in a healthy population. Clin Hemorheol Microcirc. 2015;59(4):379–17. doi:https://doi.org/10.3233/CH-141862
- Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JSR, Wharton J, Wilkins MR. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011;58(3):300–17. doi:https://doi.org/10.1016/j.jacc.2011.02.057
- de Gonzalo-Calvo D, de Luxán-Delgado B, Rodríguez-González S, García-Macia M, Suárez FM, Solano JJ, Rodríguez-Colunga MJ, Coto-Montes A. Interleukin 6, soluble tumor necrosis factor receptor I and red blood cell distribution width as biological markers of functional dependence in an elderly population: a translational approach. Cytokine. 2012;58(2):193–17. doi:https://doi.org/10.1016/j.cyto.2012.01.005
- May JE, Marques MB, Reddy V, Gangaraju R. Three neglected numbers in the CBC: The RDW, MPV, and NRBC count. Cleve Clin J Med. 2019;86(3):167–17. doi:https://doi.org/10.3949/ccjm.86a.18072
- Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862–17. doi:https://doi.org/10.1038/nrc927
- Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28(6):1054–17. doi:https://doi.org/10.1200/JCO.2009.24.9730